rSIFN-co

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NamerSIFN-co
Drug Alias NameCrystalline recombinant interferonRecombinant super interferon compoundRecombinant super compound interferon
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInterferon gamma receptor stimulantsInterferon lambda receptor stimulantsImmunostimulants +[4] 
TargetsInterferon lambda receptorInterferon gamma receptorInterferon alpha/beta receptor
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Prostatic NeoplasmsCarcinoma, Non-Small-Cell Lung +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingaporePhilippines +[4] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesSichuan Huiyang Life Science and Technology Corp
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSichuan Huiyang Life Science and Technology Corp
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Hepatitis B, Chronic
Inactive IndicationsProstatic NeoplasmsCarcinoma, Non-Small-Cell LungLung Neoplasms +[9] 

Other Information

ATC CodeN/A
Related LinksN/A